Minimal Change Disease
Conditions
Interventions
Control Group:Conventional corticosteroid regimen
Intervention Group:Low-dose rituximab combined with a short-term rapid corticosteroid tapering regimen
Sponsors
The First Affiliated Hospital of Fujian Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Age >=18 years and =3 g or urinary albumin-to-creatinine ratio >=2500 mg/g; 3.Diagnosis of MCD confirmed by renal biopsy; 4.Voluntarily agree to participate in the study and provide signed informed consent.
Exclusion criteria
Exclusion criteria: 1.Patients with MCD who have previously received glucocorticoid or other immunosuppressive therapy; 2.Renal biopsy indicates coexistence of other primary or secondary glomerular diseases, including membranous nephropathy, IgA nephropathy, focal segmental glomerulosclerosis, pauci-immune crescentic glomerulonephritis, anti-glomerular basement membrane nephritis, lupus nephritis, diabetic nephropathy, hypertensive renal damage, paraprotein-related glomerulopathy, etc.; 3.Concurrent active infectious diseases, including but not limited to the following: a. Tuberculosis infection: Positive T-SPOT.TB test result and clinical evaluation suggesting possible active tuberculosis infection; b. Hepatitis B: Positive hepatitis B surface antigen (HBsAg); c. Hepatitis C: Positive hepatitis C antibody (HCV-Ab) and positive HCV RNA test result; d. Syphilis infection: Positive Treponema pallidum antibody and positive non-treponemal test (e.g., TRUST), confirmed as active syphilis infection through further examination; e. Human immunodeficiency virus (HIV) infection: Positive HIV antibody; 4.Severe infections and other life-threatening complications; 5.Abnormal liver function (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2 times the upper limit of normal); 6.Severe cardiac or pulmonary organ dysfunction; 7.eGFR < 30 mL/min/1.73 m²; 8.Body weight less than 40 kg; 9.Pregnant women, breastfeeding women, or subjects unwilling to use effective contraception; 10.Patients with psychiatric disorders; 11.Patients allergic to rituximab or glucocorticoid components; 12.Patients with poor treatment compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum albumin;24-hour urinary protein quantification;Urine Albumin-to-Creatinine Ratio;Serum creatitine; | — |
Countries
China
Contacts
Public ContactWang Yujia
The First Affiliated Hospital of Fujian Medical University
Outcome results
None listed